SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?


To: Icebrg who wrote (794)3/23/2004 1:28:25 PM
From: Icebrg  Read Replies (1) | Respond to of 2240
 
AMG 714 - HuMax-IL15

[From Amgen's PR of today].

AMG 714 is a human monoclonal antibody directed against Interleukin-15 (IL-15) that is being developed under an agreement with Genmab S/A to treat inflammatory and autoimmune diseases. AMG 714 is currently being evaluated in Phase 2 clinical studies for rheumatoid arthritis.

Interim results suggest that AMG 714 may improve the signs and symptoms of rheumatoid arthritis. Amgen expects to complete this Phase 2 clinical evaluation in 2004.